Ossotideの中国市場

調査会社China Research and Intelligence社が発行したリサーチレポート(データ管理コード:DATA8102351)
◆英語タイトル:Investigation Report on Chinese Ossotide Market, 2018-2022
◆発行会社/調査会社:China Research and Intelligence
◆商品コード:DATA8102351
◆発行日:2018年8月
◆調査対象地域:中国
◆産業分野:製薬
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,200 ⇒換算¥237,600見積依頼/購入/質問フォーム
EnterprisewideUSD3,300 ⇒換算¥356,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Ossotideの中国市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DescriptionAccording to statistics, the incidence of rheumatoid arthritis in China is 0.2% to 0.36%, and the number of patients is up to 5 to 10 million. Like rheumatoid arthritis, osteoarthritis is one of the most common arthritis and a manifestation of articular degeneration with age. At the end of 2017, the number of people aged 60 and above reached 241 million in China, accounting for 17.3% of the total population. Some research has pointed out that over 60% of Chinese people aged 60 and above are suffering from osteoarthritis as the population is ageing. Typical symptoms of osteoarthritis are joint pains, joint deformities, and joint dysfunction, decreasing patients’ mobility and quality of life.
Ossotide can regulate bone metabolism and stimulate the proliferation of bone cells to foster the formation of new bones. It can also regulate calcium and phosphorus metabolism and increase bone calcium deposition to prevent osteoporosis. Ossotide was originally developed by Nanjing Xinbai Pharmaceutical Co., Ltd. There are many Ossotide manufacturers in China. The top 5 market players are Harbin Medisan Pharmaceutical Co., Ltd., Heilongjiang ZBD Pharmaceutical Co., Ltd., Heilongjiang Jiangshi Pharmaceutical Co., Ltd., Nanjing Xinbai Pharmaceutical Co., Ltd. and Anhui Hongye Pharmaceutical Co., Ltd. In 2017, their market share by sales revenue reached over 90%. Harbin Medisan Pharmaceutical Co., Ltd. captured the biggest market share by sales value about 35%.
According to CRI, after Ossotide was launched in China, the sales value of Ossotide kept growing before 2012 and fluctuated from 2013 to 2017. Overall, the annual sales value in China increased from less than CNY 120 million in 2007 to CNY 363 million in 2017. The Chinese Ossotide market will continue to grow in the coming years.

Topics Covered:
- Development environment of Ossotide
- Sales of Ossotide in China
- Competition pattern of Chinese Ossotide Market
- Major Ossotide manufacturers in China
- Prices of Ossotide in China
- Prospect of the Chinese Ossotide market from 2018 to 2022

*** レポート目次(コンテンツ)***

Table of Contents
1 Relevant Concepts of Ossotide
1.1 Indications for Ossotide
1.2 Development History of Ossotide in China
1.3 Patents and Government Approval on Ossotide in China

2 Sales of Ossotide in China, 2013-2017
2.1 Sales Value of Ossotide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Ossotide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Ossotide by Dosage Form in China, 2013-2017
2.3.1 Injections
2.3.2 Tablets

3 Major Ossotide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Ossotide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Harbin Medisan Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales
3.3 Heilongjiang ZBD Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales
3.4 Heilongjiang Jiangshi Pharmaceutical Co., Ltd.
3.5 Nanjing Xinbai Pharmaceutical Co., Ltd.
3.6 Anhui Hongye Pharmaceutical Co., Ltd.

4 Prices of Different Manufacturers’ Ossotide in China, 2017-2018
4.1 Harbin Medisan Pharmaceutical Co., Ltd. (Maijinli)
4.2 Heilongjiang ZBD Pharmaceutical Co., Ltd.
4.3 Heilongjiang Jiangshi Pharmaceutical Co., Ltd. (Gujie)
4.4 Nanjing Xinbai Pharmaceutical Co., Ltd. (Guzheng)
4.5 Anhui Hongye Pharmaceutical Co., Ltd. (Shundaxin)

5 Prospect of Chinese Ossotide Market, 2018-2022
5.1 Analysis on Factors Influencing Development of Ossotide in China
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Governmental Approval of Ossotide in China
Chart Sales Value of Ossotide in China, 2013-2017
Chart Sales Value of Ossotide in Parts of China, 2013-2017
Chart Sales Volume of Ossotide in China, 2013-2017
Chart Market Share of Top 5 Ossotide Manufacturers by Sales Value, 2013-2017
Chart Sales Value and Market Share of Harbin Medisan Pharmaceutical Co., Ltd.’s Ossotide in China, 2013-2017
Chart Sales Value and Market Share of Heilongjiang ZBD Pharmaceutical Co., Ltd.’s Ossotide in China, 2013-2017
Chart Sales Value and Market Share of Heilongjiang Jiangshi Pharmaceutical Co., Ltd.’s Ossotide in China, 2013-2017
Chart Sales Value and Market Share of Ossotide Injections in China, 2013-2017
Chart Sales Value and Market Share of Ossotide Tablets in China, 2013-2017
Chart Prices of Nanjing Xinbai Pharmaceutical Co., Ltd.’s Ossotide in Parts of China, 2017-2018
Chart Prices of Harbin Medisan Pharmaceutical Co., Ltd.’s Ossotide in Parts of China, 2017-2018
Chart Prices of Heilongjiang Jiangshi Pharmaceutical Co., Ltd.’s Ossotide in Parts of China, 2014



*** レポートのキーワード ***

Ossotide

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA8102351 )"Ossotideの中国市場" (英文:Investigation Report on Chinese Ossotide Market, 2018-2022)はChina Research and Intelligence社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。